#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial


Authors: Tomáš Kovárník 1;  Karel Kopřiva 2;  Jan Pudil 1
Authors‘ workplace: II. interní klinika kardiologie a angiologie 1. LF UK a VFN v Praze 1;  Kardiologické oddělení Nemocnice Na Homolce, Praha 2
Published in: Vnitř Lék 2018; 64(1): 61-64
Category: Reviews

Overview

Authors summarize trials assessing regression of coronary atherosclerosis. Special interest is devoted to imagine techniques. Authors describe in a detail methodology and results of GLAGOV trial.

Key words:
coronary atherosclerosis – intravascular ultrasound – regression


Sources

1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. JACC 2005; 46(7): 1225–1228. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2005.07.006>.

2. Nicholls SJ, Hsu A, Wolski K et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. JACC 2010; 55(21): 2399–2407. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2010.02.026>.

3. Nicholls S, Puri R, Anderson T et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA 2016; 316(22): 2373–2384. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2016.16951>.

4. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295(13): 1556–1565. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.295.13.jpc60002>.

5. Nicholls S, Ballantyne Ch, Barter P et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. N Engl J Med 2011; 365(22): 2078–2087. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1110874>.

6. Otagiri K, Tsutsui H, Kumazaki S et al. Early Intervention With Rosuvastatin Decreases the Lipid Components of the Plaque in Acute Coronary Syndrome. Circ J 2011; 75(3): 633–641.

7. Nair A, Margolis P, Kuban B et al. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. Eurointervention 2007; 3(1): 113–120.

8. Puri R, Libby P, Nissen SE et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovascular Imaging 2014; 15(4): 380–388. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjci/jet251>.

9. Garcia-Garcia H, Gogas B, Serruys PW et al. IVUS-based imaging modalities for tissue characterization: similarities and differences. Int J Cardiovasc Imaging 2011; 27(2): 215–224. Dostupné z DOI: <http://dx.doi.org/10.1007/s10554–010–9789–7>.

10. Waxman S, Ishibashi F, Caplan JD. Rationale and use of near-infrared spectroscopy for detection of lipid-rich and vulnerable plaques. J Nucl Cardiol 2007; 14(5): 719–728. Dostupné z DOI: <http://dx.doi.org/10.1016/j.nuclcard.2007.08.001>.

11. Kini AS, Baber U, Kovacic JC et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). JACC 2013; 62(1): 21–29. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.03.058>.

12. Tearney G, Regar E, Akasaka T et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. JACC 2012; 59(12): 1058–1072. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.09.079>.

13. Hattori K, Ozaki Y, Ismail T et al. Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter – IVUS. JACC Cardiovasc Imaging 2012; 5(2): 169–177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcmg.2011.11.012>.

14. Kataoka Y, Andrews J, Puri R et al. Lipid lowering therapy to modify plaque microstructures. Insights from optical coherency tomography imaging. J Atheroscler Thromb 2017; 24(4): 360–372. Dostupné z DOI: <http://dx.doi.org/10.5551/jat.RV16009>.

15. Ueda Y, Hiro T, Hirayama A et al. Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque – The ZIPANGU Study. Circ J 2017; 81(11): 1611–1619. Dostupné z DOI: <http://dx.doi.org/10.1253/circj.CJ-17–0193>.

16. Hougaard M, Hansen HS, Thayssen P et al. Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial Intravascular ultrasound with iMap: the OCTIVUS trial. Cardiovasc Revasc Med 2017; 18(2): 110–117. Dostupné z DOI: <http://dx.doi.org/10.1016/j.carrev.2016.11.010>.

17. Tsujita K, Sugiyama S, Sumida H et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention The Multicenter Randomized Controlled PRECISE-IVUS Trial. JACC 2015; 66(5): 495–507. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2015.05.065>.

18. Cannon Ch, Blazing M, Giugliano R et al. for the IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387–2397. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1410489>.

19. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016; 248: 117–122. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.03.010>.

20. Puri R, Nissen SE, Ballantyne Ch et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J 2013; 34(24): 1818–1825. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht084>.

21. Hwang DS, Shin ES, Kim SJ et al. Early Differential Changes in Coronary Plaque Composition According to Plaque Stability Following Statin Initiation in Acute Coronary Syndrome: Classification and Analysis by Intravascular Ultrasound-Virtual Histology. Yonsei Med J 2013; 54(2): 336–344. Dostupné z DOI: <http://dx.doi.org/10.3349/ymj.2013.54.2.336>.

22. Stegman B, Shao M, Nicholls SJ et al. Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. Atherosclerosis 2016; 254: 78–84. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.059>.

23. Sabatine M, Giugliano R, Keech A et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.

24. Thondapu V, Bourantas Ch, Foin N et al. Biomechanical stress in coronary atherosclerosis: emerging insights from computational modeling. Eur Heart J 2017; 38(2): 81–92. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehv689>.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 1

2018 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#